Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913004 | 0.87 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL277999 | 0.85 | TSHR (0.31) | ALDH1A1DPP4 | |
| SCHEMBL15901572 | 0.82 | LMNA (0.32) | ALDH1A1DPP4 | |
| SCHEMBL14261830 | 0.82 | LMNA (0.32) | ALDH1A1DPP4 | |
| Hydrochloric Acid SCHEMBL4307349 | 0.82 | KDM4E (0.30) | DPP4 | |
| SCHEMBL4315116 | 0.81 | ALDH1A1 (0.45) | ALDH1A1ARVDR | |
| SCHEMBL4318301 | 0.81 | ALDH1A1 (0.38) | ALDH1A1DPP4 | |
| SCHEMBL4667751 | 0.78 | — | — | |
| SCHEMBL7963768 | 0.78 | GSR (0.35) | ALDH1A1DPP4 | |
| SCHEMBL10045123 | 0.77 | CYP2C19 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-2004193-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | ALDH1A1 1707/4885AR 4005/4885VDR 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.